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We are developing inactivated and live-attenuated rabies virus (RABV) vaccines expressing Ebola virus
(EBOV) glycoprotein for use in humans and endangered wildlife, respectively. Here, we further
characterize the pathogenesis of the live-attenuated RABV/EBOV vaccine candidates in mice in an
effort to deﬁne their growth properties and potential for safety. RABV vaccines expressing GP (RV-GP)
or a replication-deﬁcient derivative with a deletion of the RABV G gene (RVDG-GP) are both avirulent
after intracerebral inoculation of adult mice. Furthermore, RVDG-GP is completely avirulent upon
intracerebral inoculation of suckling mice unlike parental RABV vaccine or RV-GP. Analysis of RVDG-GP
in the brain by quantitative PCR, determination of virus titer, and immunohistochemistry indicated
greatly restricted virus replication. In summary, our ﬁndings indicate that RV-GP retains the
attenuation phenotype of the live-attenuated RABV vaccine, and RVDG-GP would appear to be an
even safer alternative for use in wildlife or consideration for human use.
Published by Elsevier Inc.Introduction
Several viruses from the Ebolavirus genus and Marburgvirus
genus, Family Filoviridae, cause severe and often fatal viral
hemorrhagic fever in humans and nonhuman primates (Sanchez
et al., 2007). The high case fatality rate, public health threat in
Africa, and biodefense concerns associated with these viruses
have resulted in considerable effort and progress in ﬁlovirus
vaccine development (Bradfute et al., 2011; Geisbert et al.,
2010). Several vaccination strategies have been developed that
confer protection in animal models, but issues of safety, preexist-
ing vector immunity, production, or lack of commercial interest
have slowed progress (Bukreyev et al., 2010; Geisbert et al., 2010;
Hensley et al., 2010; Sun et al., 2009; Warﬁeld et al., 2007). An
Ebola virus (EBOV) vaccine would be directed for use in humans
at risk of infection in Africa as well as for healthcare providers,
ﬁrst responders, soldiers, or travelers. A second application forInc.
rated Research Facility, 8200
1 301 619 5029.
and Immunology Jefferson
uth, 10th St 531, BLSB,
(M.J. Schnell),EBOV vaccines would be utilization in endangered wildlife at risk
of lethal EBOV disease including gorillas and chimpanzees of
Central Africa. Studies have indicated that EBOV outbreaks have
resulted in numerous nonhuman primate (NHP) deaths in Gabon
and the Republic of Congo, which could hinder conservation
efforts (Bermejo et al., 2006; Leroy et al., 2004; Rouquet et al.,
2005). A vaccine to protect these at risk animals would have a
second critical beneﬁt to humans. As EBOV is a zoonotic disease
with documented human outbreaks arising from contact with
diseased nonhuman primates (NHPs) (Mahanty and Bray, 2004),
prevention of disease in NHPs might reduce the frequency of
transmission to humans.
We sought to identify a vaccine platform for EBOV and other
ﬁloviruses of public health importance that would result in
promising candidates for use in both humans and endangered
wildlife. To this end, we have developed (a) replication-compe-
tent, (b) replication-deﬁcient, and (c) chemically inactivated
rabies virus (RABV) vaccines expressing EBOV (Zaire; Mayinga)
glycoprotein (GP) (Blaney et al., 2011). The recombinant RABV
vaccine platform has been used to generate vaccine candidates for
several viral pathogens and is characterized by strong replication,
potent induction of humoral and cellular immunity, and genetic
stability of inserts (Gomme et al., 2011; Mebatsion et al., 1996).
Our primary focus is the development of an inactivated vaccine
for use in humans based on the potential for superior safety and
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vated RABV vaccine that is widely used in humans. As RABV is still
a considerable public health issue in Africa with an estimated
24,000 deaths reported yearly (Cleaveland et al., 2002; Knobel
et al., 2002; Schnell et al., 2010), a bivalent vaccine that confers
protection from RABV and EBOV would be an economical and
efﬁcient public health tool. However, in addition to the develop-
ment of inactivated RABV/EBOV vaccines, the parental recombi-
nant RABV vaccine used to generate the RABV/EBOV vaccine
candidates is derived from the SAD B19 strain, which is used for
wildlife vaccination by baiting in Europe suggesting additional
applications of our vaccine candidates (Vos et al., 1999; Vos et al.,
2002). Therefore, live-attenuated RABV/EBOV vaccines could be
considered for use in Africa in an analogous campaign to protect
at risk NHPs from lethal EBOV infections.
Here, our goal was to further deﬁne the virological properties
and virulence of the replication competent, RV-GP, and replica-
tion deﬁcient, RVDG-GP, vaccine candidates that we have pre-
viously described (Blaney et al., 2011). Both RV-GP and RVDG-GP,
which has a deletion removing the entire RABV glycoprotein
(G) gene, were found to be avirulent upon peripheralFig. 1. Recombinant viruses. (A) Negative sense RNA genomes are illustrated for
the parental rabies vaccine, RVA(p), which was previously termed BNSP. (B) The
further attenuated derivative, RVA, contains an attenuating mutation at amino
acid 333 of RABV G resulting in an Arg-Glu change, which restricts neuroviru-
lence of RABV vaccines in adult mice. (C) RV-GP encodes EBOV Mayinga strain GP
between RABV N and P from the RVA vector. (D) RVDG-GP contains a deletion in
the RABV G gene and is propagated on a complementing cell line, BSR-G cells,
which express G.
Fig. 2. Virus yields in cell culture. (A) Vero cells were infected with indicated viruses
infected at an MOI of 0.01. Infected monolayers were incubated at 37 1C for indic
concentrations were determined by viral focus assay. Dashed line indicates limit of deadministration in mice. Each bivalent vaccine candidate induced
strong humoral immunity to RABV G and EBOV GP, and conferred
protection from both lethal RABV and mouse-adapted (MA) EBOV
challenge in mice (Blaney et al., 2011). Here we further char-
acterize the high degree of attenuation of these vaccine candi-
dates in comparison to the existing parental live-attenuated RABV
vaccine already used in wildlife.Results
RABV vaccine vectored EBOV GP vaccine candidates and their
replication in cell culture
The construction and propagation of the recombinant vaccine
viruses studied here has been previously described. The parental
RABV vaccine vector, RVA(p), is a recombinant derivative of the
SAD B19 RABV vaccine strain, which has been used as a live oral
vaccine for wildlife in Europe (Fig. 1) (McGettigan et al., 2003).
RVA, a further attenuated vaccine vector containing an Arg-Glu
change at amino acid 333 of RABV G, was used to generate RV-GP,
which expresses EBOV Mayinga glycoprotein (GP) (Blaney et al.,
2011). RVDG-GP expresses EBOV Mayinga GP but contains a
deletion of the RABV G gene requiring propagation on trans-
complementing BSR-G cells (Blaney et al., 2011).
We ﬁrst sought to determine the effect of EBOV GP expression
on replication of the RABV vaccines in cell culture. Robust
replication in appropriate cell culture is critical to the develop-
ment of a cost-effective vaccination strategy. Here we present the
optimal conditions for replication of RV-GP and RVDG-GP. We
ﬁrst evaluated the replication of the vaccine viruses in Vero cells
(Fig. 2A), which are a cell line currently in use for the production
of human vaccines. At a multiplicity of infection (m.o.i.) of 5, RV-
GP reached a virus titer of 8.0 Log10FFU/ml at ﬁve days post-
infection. Importantly, the expression of EBOV GP does not appear
to decrease the virus production when the vectored viruses are
compared to levels reached by the control RABV viruses,
RVA(p) or RVA. We also assessed the replication of the RABV G
deletion virus, RVDG-GP, in (A) Vero cells and (B) BSR-G cells. As
expected due to its design as a replication-deﬁcient virus, RVDG-
GP did not replicate in Vero cells (Fig. 2A). In contrast, RVDG-GP
reached virus titers of 7.4 Log10FFU/ml in BSR-G cells expressing
RABV G (Fig. 2B). These results conﬁrm the restricted growth
properties of RVDG-GP but indicate that the vaccine candidate
can be propagated to high levels under appropriate conditions
(e.g. trans-complementing cells) demonstrating that each vaccineat an MOI of 5. BSR-G cells (a BHK cell derivative that expresses RABV G) were
ated time, and samples were removed for determination of virus yield. Virus
tection.
Fig. 4. RV-GP and RVDG-GP are avirulent after intracerebral (i.c.) inoculation of
adult mice. Groups of eight four week-old mice were injected i.c. with 1105 FFU
of the indicated virus and monitored daily for survival for 28 day.
Table 1
RVDG-GP (LD504105 FFU) has at least a 19,000-fold reduction in
neurovirulence when compared to the attenuated RVA
(LD50¼5.2 FFU) by i.c. injection of suckling mice.
Virus Dose Survivala Mean day of endpoint
(FFU) (%) (days 7 SE)
RVA 104 0 8.870.3
102 0 9.870.4
101 30 10.970.4
100 100 n/a
RVDG-GP 105 100 n/a
a Five-day-old Swiss Webster mice (n¼10) were inoculated IC
with indicated dosage of virus and monitored for signs of ence-
phalitis for 21 day.
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effort at optimization thus far.
Neuroinvasiveness in immunodeﬁcient mice
Our previous results have indicated that peripheral injection of
RABV vaccine viruses expressing GP (with or without RABV G) by
the intramuscular (i.m.), intranasal (i.n.), or intraperitoneal (i.p.)
route in immunocompetent mice resulted in no morbidity or
moribundity (Blaney et al., 2011). Here, we next sought to further
determine the safety proﬁle of our vaccine candidates by periph-
eral administration to immunodeﬁcient ICR-SCID mice (Fig. 3).
Groups of eight adult ICR-SCID mice were injected i.m. in the hind
leg with vehicle (PBS) or 1106 FFU of RVA(p), RVA, RV-GP, or
RVDG-GP. Mice were monitored daily for signs of infection and
survival for 84 day. Results indicated that 2 of 8 and 1 of 8 RVA(p)-
and RVA-infected mice succumbed to infection, respectively.
Similarly, 1 of 8 mice injected with RV-GP succumbed to infec-
tion. No mice in the vehicle (PBS) or RVDG-GP groups succumbed
to infection. These results indicated that GP expression did not
increase the virulence of the parent RABV vaccine vector in mice
without functional adaptive immunity, which is a further indica-
tion of the safety of these vaccine candidates. Furthermore,
RVDG-GP showed no virulence in immunodeﬁcient mice.
Neurovirulence in adult and suckling mice
RVA(p) retains neurovirulence upon intracerebral (i.c.) infec-
tion of adult mice. However, RVA which was used to generate RV-
GP is avirulent when administered by i.c. injection by virtue of the
Arg-Glu change at amino acid 333 of RABV G (McGettigan et al.,
2003). We sought to determine if expression of EBOV GP would
modify neurovirulence in adult mice. Groups of eight four-week-
old mice were injected i.c. with vehicle or 1105 FFU of RVA(p),
RVA, RV-GP, or RVDG-GP, and monitored daily for survival (Fig. 4).
As expected, RVA(p) was lethal upon i.c. injection with 100% of
mice succumbing by day 10. In contrast, 100% of mice inoculated
with RVA, RV-GP and RVDG-GP survived infection, and there was
no evidence of any clinical signs. Thus, in adult mice, both RV-GP
and RVDG-GP lack neurovirulence.
In contrast to results observed in adult mice, both RVA(p) and
RVA retain neurovirulence when administered to suckling mice
by the i.c. route (Blaney et al., 2011). RV-GP and RVDG-GP were
previously evaluated for neurovirulence by i.c. injection ofFig. 3. Addition of GP to RVA does not increase neuroinvasiveness in immunodeﬁ-
cient mice. Groups of 8 4–6 week-old SCID mice were injected i.m. in the hind leg
with 1106 FFU of the indicated virus and monitored daily for survival for 84 days.suckling mice and RV-GP was also found to be lethal (Blaney
et al., 2011). In contrast, RVDG-GP was found to be avirulent in
suckling mice injected i.c. at the highest dose tested, 6104 FFU.
Here we sought to conﬁrm and expand these results by admin-
istration of a higher dose, 1105 FFU, of RVDG-GP in suckling
mice by the i.c. route (Table 1). RVDG-GP was again found to
induce no disease in suckling mice. In contrast RVA was 100%
lethal at 104 and 102 FFU while administration of 101 and 101 FFU
resulted in 30% lethality and no lethality, respectively. The LD50
for RVA was determined to be 5.2 FFU while the LD50 for RVDG-
GP was 4105 FFU. These results indicate that RVDG-GP has at
least a 19,000-fold reduction in neurovirulence compared to RVA
as compared by LD50.
Analysis of RVDG-GP replication in suckling mouse brain
RVA and RV-GP lack neurovirulence in adult mice but retain it
in suckling mice. In contrast, RVDG-GP appears to lack neuro-
virulence in both adult and suckling mice. Therefore, we next
attempted to compare the vaccine viruses for growth properties
in suckling mouse brain and to determine if RVDG-GP has any
capacity for replication in the brain. Five-day-old Swiss Webster
mice were inoculated i.c. with 1105 FFU of RVA(p), RVA, RVA-
GP, or RVDG-GP (Fig. 5). On days 1, 3, 5, 6, 7, 9, 14, and 21, three
Fig. 5. Replication of vaccine candidates in suckling mouse brain assayed by
quantitative PCR. Five-day-old Swiss Webster mice were inoculated i.c. with
1105 FFU of the indicated virus. On days 1, 3, 5, 7, 9, 14, and 21, three mice per
group were sacriﬁced and brain homogenates were generated. The level of viral
genomic RNA was determined by a RABV NP-speciﬁc quantitative RT-PCR assay.
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were generated, and levels of viral genomic RNA were determined
by quantitative reverse transcription polymerase chain reaction
(qRT-PCR) targeting the RABV N gene. As expected, viral load was
highest in the RVA(p) group, peaking at nearly 10.0 Log10genomic
equivalents/mg of total RNA. Peak viral load of RVA and RV-GP
were approximately 10-fold reduced and delayed when compared
to RVA(p). As expected, no mice injected with these viruses
survived past day 9. In contrast, mice injected with RVDG-GP
survived to study end and reached a peak viral genomic load in
the brain at day 9 of approximately 7.0 Log10genomic equiva-
lents/mg of total RNA which is approximately 1,000-fold reduced
from levels observed for RVA(p). These results indicate that
although RVDG-GP is avirulent upon i.c. injection of suckling
mice, viral mRNA is expressed and/or the viral genome retains at
least some capacity to amplify, persisting to at least day 21.
We next sought to determine if infectious virus could be
recovered from the brains of RVDG-GP-infected mice in compar-
ison to RVA. Five-day-old Swiss Webster mice were inoculated i.c.
with 1105 FFU of RVA or RVDG-GP. On days 1, 3, 5, 7, 9, 14, 21,
28, 35, and 42, three surviving mice per group were euthanized,
and brain homogenates were generated and assayed for focus
formation on Vero cells and BSR-G cells (Fig. 6). Analysis of RVA
replication by titration of brain homogenates in Vero cells
indicated that virus replication was robust as expected with mean
peak virus titers reaching 9.3 Log10FFU/g. In contrast, when
samples of RVDG-GP were observed when brain homogenates
were titrated in Vero cells, no detectable viral foci were observed.
However, titration of brain homogenates in BSR-G cells demon-
strated that RVDG-GP did replicate in the brain to a mean peak
virus titer of 4.7 Log10FFU/g, albeit at a greatly reduced level when
compared to RVA (8.8 Log10FFU/g). For RVDG-GP, infectious virus
was detectable and peaked at day 7 followed by a reduction to
undetectable virus levels by day 21. By comparison of mean peak
virus titer in BSR-G cells, RVDG-GP appears to have an approxi-
mately 10,000-fold reduction in the ability to replicate in the
brain when compared to RVA.Histopathological and immunohistochemical analysis of RVDG-GP
replication in suckling mouse brain
Based on the indication of limited genomic and viral replica-
tion of RVDG-GP in the brain, we next sought to compare the
evidence of viral spread and resulting inﬂammation associated
with RVA and RVDG-GP infection using histopathological (H&E)
and immunohistochemical (IHC) analysis. Five-day-old Swiss
Webster mice were inoculated i.c. with 1105 FFU of RVA and
RVDG-GP. On days 1, 3, 5, 7, 9, 14, and 21, three surviving mice
per group were euthanized and brains were processed for H&E or
IHC analysis as described in the Materials and Methods. Inﬂam-
mation and anti-RABV immunohistochemical staining were semi-
quantitatively scored in the cerebellum and hippocampus in each
of three brains per group using a 0–3 scale (0¼none, 1¼mild,
2¼moderate, and 3¼severe). Mean severity scores for menin-
goencephalitis and antigen staining in RVA- and RVDG-GP-
infected brains are summarized in Fig. 7. Inﬂammation in the
cerebellum and hippocampus of RVA-infected brains peaked on
days 5–9 reaching mean scores of 2.5 to 3.0, while RVDG-GP-
infected brains had more constant scores ranging from approxi-
mately 0.5 to 1.5 during the 3 week study. Analysis of the
presence of viral antigen also indicated that staining peaked in
the cerebellum and hippocampus of RVA-infected brains on day 5,
7, and 9 although hippocampal antigen staining was more
pronounced with scores ranging from 2.0 to 3.0. Analysis of
RVDG-GP-infected brains did not appear to demonstrate evidence
of viral spread as antigen staining was consistently low through-
out the study ranging from 0.0 to 1.3.
In the cerebellum of RVA-infected mice, the cortical cerebellar
architecture became progressively disrupted by a moderate to
markedly dense inﬂammatory inﬁltrate composed primarily of
neutrophils (Fig. 8). The inﬁltrate was most dense within the
granule cell and Purkinje cell layers, and extended to a lesser
extent into the molecular and outer granular cell layers as well as
the meninges. Anti-RABV immunohistochemistry revealed abun-
dant cytoplasmic staining within inﬂammatory cells and neurons.
In contrast, the cerebellar architecture remained intact in RVDG-
GP-infected brains. Minimal to mild neutrophilic and lymphocytic
inﬂammation was found in most animals; in two individuals the
degree of inﬂammation was classiﬁed as moderate. Anti-RABV
immunohistochemistry revealed either no staining or occasional
staining within inﬂammatory cells or neurons.
Analysis of the hippocampus from RVA-infected brains indi-
cated that over the course of the study, the hippocampal archi-
tecture became progressively disrupted by a moderate to
markedly dense inﬂammatory inﬁltrate composed primarily of
neutrophils and lymphocytes (Fig. 9). The destruction was most
marked within the CA3, CA4, and dentate gyrus regions of the
hippocampus. Anti-RABV immunohistochemistry revealed dis-
crete cytoplasmic staining within large numbers of inﬂammatory
cells, most commonly neutrophils, and to a lesser extent, within
neurons. In RVDG-GP-infected brains, the hippocampal architec-
ture remained intact. Occasionally, diffusely distributed neutro-
phils and lymphocytes were seen, but the overall degree of
inﬂammation was minimal to mild. Anti-RV immunohistochem-
istry revealed either no staining or occasional staining within
isolated inﬂammatory cells or neurons.Discussion
In addition to the demonstration of immunogenicity and
clinical efﬁcacy for a live virus vaccine candidate, the demonstra-
tion of vaccine safety and knowledge of the virological properties
of live vaccines is paramount. For live vaccines that may cause
Fig. 6. Replication of RVDG-GP in suckling mouse brain determined by virus focus assay. Five-day-old Swiss Webster mice were inoculated i.c. with 1105 FFU of the
indicated virus. On days 1, 3, 5, 7, 9, 14, 21, 28, 35, and 42, three mice per group were sacriﬁced and brain homogenates were generated. The level of infectious virus was
determined by focus-forming assay on (A) Vero cells or (B) BSR-G cells).
Fig. 7. Histopathological and immunohistochemical analysis of RVDG-GP in suckling mouse brain. Five-day-old Swiss Webster mice were inoculated i.c. with 1105 FFU
of the indicated virus. On days 1, 3, 5, 7, 9, 14, and 21, three mice per group were sacriﬁced and brains were processed for (A, B) H&E or (C, D) anti-RABV NP IHC analysis as
described in the Materials and Methods. Inﬂammation and immunohistochemical staining were semi-quantitatively scored in the (A, C) cerebellum and (B, D)
hippocampus in each of three brains per group using a 0–3 scale (0¼none, 1¼mild, 2¼moderate, and 3¼severe). The mean severity score is indicated. X indicates that all
mice from the RVA group had succumbed to infection and were unavailable for analysis.
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deﬁne neurotropic viral pathogenesis require investigation, neu-
roinvasiveness and neurovirulence. Neuroinvasiveness describes
the ability of a virus to invade the CNS when inoculated at a
peripheral site, while neurovirulence describes the capacity of a
virus to induce disease when administered directly into the brain.
While live RABV vaccine vectors have previously been used as a
safe and efﬁcacious platform to generate vaccine candidates
against several pathogens (Faber et al., 2005; Faul et al., 2009;
McGettigan et al., 2003; Mustafa et al., 2011; Siler et al., 2002), we
sought here to fully characterize the viral pathogenesis and safetyof our RABV/EBOV vaccine candidates in comparison to the live
RABV vaccine that has been used extensively for wildlife vaccina-
tion in Europe.
Previous analysis of RV-GP and RVDG-GP in immunocompe-
tent mice demonstrated a complete lack of neuroinvasiveness
upon intranasal, intraperitoneal, and intramuscular administra-
tion of virus demonstrating that expression of EBOV GP did not
increase virulence of the RVA(p) (Blaney et al., 2011). Here, i.m.
administration of RV-GP and RVDG-GP to immunodeﬁcient mice
was utilized as an even more stringent assay for neuroinvasive-
ness. We demonstrated that RVA(p) and RVA retain a limited
Fig. 8. Histopathology (H&E) and anti-RABV NP immunohistochemistry (IHC) of the cerebellum. Representative H&E (A, B) and IHC (C, D) of cerebellum from suckling mice
inoculated i.c. with RVA (A, C) or RVDG-GP (B, D). Size indicated is the objective magniﬁcation. (A) Marked inﬁltration and disruption of the Purkinje cell layer (yellow
dotted line) and granule cell layer (area between the yellow and green dotted lines), and to a lesser extent the molecular layer (pink area to the right of the yellow dotted
line), by large numbers of neutrophils and lymphocytes. Also note dilatation and congestion of the capillaries (asterisks). (B) Essentially normal cerebellum with well-
delineated molecular, Purkinje, and granule cell layers, and normal capillaries (see A for explanation of annotations). (C) Anti-RABV NP IHC showing numerous
immunopositive (brown) neurons and inﬂammatory cells. (D) Anti-RABV NP IHC showing minimal immunopositivity (brown).
Fig. 9. Histopathology (H&E) and anti-RABV NP immunohistochemistry (IHC) of the hippocampus. Representative H&E (A, B) and IHC (C, D) of hippocampus from suckling
mice inoculated i.c. with RVA (A, C) or RVDG-GP (B, D). Size indicated is the objective magniﬁcation. (A) Marked inﬁltration and disruption of the CA3-CA4 regions (boxed
area) by neutrophils and lymphocytes. Also note rarefaction (paleness) of the surrounding neuropil and prominent capillaries lined by reactive endothelium. Inset shows
higher magniﬁcation of the CA3-CA4 region containing large numbers of neutrophils, lymphocytes, and prominent capillaries. (B) Essentially normal hippocampus. (C)
Anti-RABV NP IHC of the CA3-CA4 region showing large numbers of immunopositive (brown) inﬂammatory cells. (D) Anti-RABV NP IHC of the CA3-CA4 region showing no
signiﬁcant immunopositivity (brown).
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induced disease in one of eight immunodeﬁcient mice. However,
no mice inoculated with RVDG-GP showed signs of disease
indicating that it may have enhanced attenuation when compared
to RVA(p), a recombinant derivative of the current live-attenuated
wildlife RABV vaccine used in Europe.
Analysis of neurovirulence was conducted in adult and suck-
ling immunocompetent mice. We demonstrated that RVA(p) is
lethal in adult mice when administered by the i.c. route, but that
RVA, a further attenuated vaccine vector containing an Arg-Glu
change at amino acid 333 of RABV G, was avirulent under the
same conditions as has been previously reported (McGettigan
et al., 2003). Importantly, both RV-GP (derived from RVA) and
RVDG-GP showed no neurovirulence in adult mice. In contrast,
we previously reported that both RVA and RV-GP retain neuro-
virulence in suckling mice analogous to RVA(p), while RVDG-GP
was found to be avirulent (Blaney et al., 2011). Here we conﬁrmed
that RVDG-GP does not induce disease when administered i.c. to
suckling mice and has at least a 19,000-fold reduction in neuro-
virulence when compared to RVA. In summary, our results in
mice indicate that RV-GP (lack of neurovirulence in adult mice)
and RVDG-GP (lack of neurovirulence in adult and suckling mice)
are both further attenuated for neurotropism than the current live
RABV vaccine which has an excellent safety proﬁle in Europe
where millions of live-baited vaccines have been distributed.
In addition to the lack of neurovirulence observed for RVDG-
GP, the virus was shown not to proliferate in Vero cells; replica-
tion is restricted to the BSR-G trans-complementing cell line.
Therefore, we sought to determine if the virus had any capability
to replicate in the CNS. RVDG-GP showed limited evidence of viral
mRNA expression and/or genome ampliﬁcation as assayed by RT-
qPCR and production of infectious virus between days 7 and 14
which could only be detected on BSR-G cells. However, immuno-
histochemical analysis indicated that no morphologically detect-
able virus spread occurred as was readily observed for RVA. These
results could suggest that upon i.c. inoculation, RVDG-GP infected
a small number of neurons or inﬂammatory cells mediated by the
G present in virions followed by limited replication of the viral
genome and production of virions which may contain residual G
from the infecting RVDG-GP. However, the virus was unable to
spread in the CNS because of the absence of additional expression
of RV G. These results further support observations that RVDG-GP
has increased attenuation when compared to RVA(p) and should
be pursued as a vaccine candidate.
The demonstration of attenuation of RV-GP and RVDG-GP
described here and the previous characterization of immunogeni-
city and protective efﬁcacy in mice strongly support their con-
sideration for use as wildlife vaccines. Both vaccine candidates
induced strong humoral immunity to RABV and EBOV and
conferred protection from RABV and MA-EBOV challenge in mice
(Blaney et al., 2011). The ability of vaccination with RVDG-GP to
confer protection from RABV challenge indicates that the RABV G
incorporated into the virions from the complementing cell line is
sufﬁcient to induce immunity to RABV. Use of these vaccine
candidates in threatened NHP populations, which are highly
susceptible to lethal EBOV outbreaks, could serve as a conserva-
tion success as ﬁeld research over the past decade has indicated
that lethal EBOV outbreaks have affected chimpanzee and parti-
cularly western gorilla populations in Gabon and the Democratic
Republic of Congo (Bermejo et al., 2006; Le Gouar et al., 2009;
Leroy et al., 2004; Vogel, 2006, 2007). With the successful history
of vaccination of wildlife against RABV using dispersed baits
containing the SAD B19 vaccine strain in Europe, one could
consider using the live-attenuated RABV/EBOV vaccines in a
similar manner in Africa. The introduction of SAD B19 RABV
vaccine into Europe and safe dispersal of over 70 million vaccinebaits since the 1980s provide a strong framework for this
endeavor. Analysis of safety and immunogenicity of RV-GP and
RVDG-GP in NHPs administered oral vaccinations will be evalu-
ated in the future. It is important to note that the interaction of
humans and infected NHPs has been associated with transmission
of EBOV to humans and initiation of subsequent outbreaks;
therefore, prevention of disease in NHPs may also serve to limit
EBOV transmission into the human population.
Finally, it should be noted that although we are focused on the
development of an inactivated RABV/EBOV vaccine for humans,
RV-GP and particularly RVDG-GP could be considered for use in
humans as well. Live-attenuated vaccines are commonly asso-
ciated with stronger T cell responses and more durable immunity,
but the drawback of safety concerns in humans would be an issue
requiring careful consideration. However, the growth restriction
of RVDG-GP and absence of neurovirulence in mice indicates that
RABV vectored vaccines with a deletion in G, such as RVDG-GP or
an analogous, previously described human immunodeﬁciency
virus vaccine candidate (Gomme et al., 2010), warrant further
consideration for development as human vaccines.Materials and methods
Viruses
The recovery and propagation of the recombinant vaccine
viruses used in this study have been described previously
(Blaney et al., 2011; McGettigan et al., 2003). RVA(p) (rabies virus
vaccine parent) serves as the parent rabies vaccine vector (pre-
viously termed BNSP) and is a recombinant virus derived from the
SAD B19 RABV wildlife vaccine. RVA is a further attenuated
derivative generated by introduction of a point mutation which
results in an Arg-Glu change at amino acid 333 of RABV G
(previously termed BNSP333). RV-GP was generated by introduc-
tion of EBOV Mayinga GP between the N and P gene of RVA.
RVDG-GP also expresses EBOV Mayinga GP but contains a dele-
tion of the RABV G gene requiring propagation on trans-comple-
menting BSR-G cells. BSR cells were originally derived from BHK-
21 cells; BSR-G cells stably express RABV G upon induction with
doxycycline (Gomme et al., 2010).
Viral growth curves
One-day old conﬂuent 25 cm2 ﬂasks of Vero E6 or BSR-G cells
were infected with vaccine viruses at an m.o.i. of 5 for a one-step
growth curve or m.o.i. of 0.01 for a multi-step growth curve,
respectively. Brieﬂy, viruses were diluted in Cellgro Complete
Serum free media (CCSFM, Mediatech), added to respective ﬂasks,
and incubated at 37 1C, 5%CO2 for 1 h. Inocula were removed, and
cells were washed 3x with PBS to remove unadsorbed virus. Five
mls of CCSFM was added to each ﬂask, and ﬂasks were incubated
at 37 1C, 5%CO2. 100 mL of cell supernatants were removed at the
indicated time points after infection. Samples were titered in
duplicate using the respective cell lines on which they were
grown as described previously (Gomme et al., 2010; Wirblich and
Schnell, 2010).
Neuroinvasiveness in immunodeﬁcient mice
All animal procedures described in this manuscript were
conducted according to animal study protocols that were
approved by the NIAID Institutional Animal Care and Use Com-
mittee. For analysis of neuroinvasiveness in immunodeﬁcient
mice, four to six week old female SCID mice (ICRSC-F; Taconic,
Germantown, NY) were inoculated intramuscularly (i.m.) with
A.B. Papaneri et al. / Virology 434 (2012) 18–26 25either vehicle or 1106 FFU of vaccine viruses. Mice were
counted and monitored for indications of encephalitis or other
clinical signs daily. Moribund mice were euthanized immediately.
Neurovirulence
For evaluation of neurovirulence in adult mice, groups of eight
four to ﬁve week-old female BALB/c mice were inoculated
intracerebrally (i.c.) with either vehicle or 105 FFU of RVA(p),
RVA, RV-GP, or RVDG-GP. Mice were counted and monitored for
indications of encephalitis or other clinical signs daily for four
weeks. Moribund mice were euthanized immediately. For evalua-
tion of neurovirulence in suckling mice, litters of 10 ﬁve-day-old
Swiss Webster mice were inoculated i.c. with varying doses of
RVA or RVDG-GP as previously described (Blaney et al., 2011).
Mice were counted and monitored for indications of encephalitis
or other clinical signs daily for three weeks. Moribund mice were
euthanized immediately.
The level of viral genomic RNA in suckling mouse brain was
assayed by quantitative PCR. Five-day-old Swiss Webster mice
were inoculated i.c. with 1105 FFU of RVA or RVDG-GP. On days
1, 3, 5, 7, 9, 14, and 21, three mice per group were sacriﬁced.
Brains were removed and stored in RNAlater (Ambion) at 4 1C
until processing at which time they were weighed. RLT buffer
(Qiagen) containing 10 ml/ml of b-mercaptoethanol was then
added to each brain to result in a 300 mg/ml concentration, and
brains were homogenized using a handheld homogenizer and
disposable probes (Omni International). RNA was isolated from
30 mg of each brain using an RNeasy kit (Qiagen), aliquotted and
stored at 80 1C until use. Reverse transcription was performed
using a Transcriptor High Fidelity cDNA Synthesis Kit (Roche)
with primer RP381 (5-ACA CCC CTA CAA TGG ATG C-3) for RABV
N synthesis or 18S antisense primer (5-GGC CTC GAA AGA GTC
CTG TA-3) for mouse 18S synthesis, which was used as a reference
gene. Real-time PCR was performed on an ABI 7900HT Fast
machine using a Dynamo Probe qPCR kit (Thermo Scientiﬁc)
(Fig. 5). The following primers and probes were used: mouse
18S rRNA sense primer (5-GGG GAA TCA GGG TTC GAT-3), mouse
18S rRNA antisense primer (5-GGC CTC GAA AGA GTC CTG TA-3),
RABV N RNA sense primer (5-AGA AGG GAA TTG GGC TCT G-3),
RABV N RNA antisense primer (5-TGT TTT GCC CGG ATA TTT TG-
3), RABV N RNA probe (5-CGT CCT TAG TCG GTC TTC TCT TGA GTC
TGT-3), and mouse 18S probe (5-CTG AGA AAC GGC TAC CAC ATC
CAA GGA A-3). Custom primers and probes were purchased from
Applied Biosystems.
For determination of infectious virus titers in suckling mouse
brain, brain homogenates were collected and quantitated by focus
forming assay. Brieﬂy, ﬁve-day-old Swiss Webster mice were
inoculated i.c. with 1105 FFU of the indicated virus. On days
1, 3, 5, 7, 9, 14, 21, 28, 35, and 42, three mice per group were
sacriﬁced and brains were removed, immediately frozen on dry
ice, and stored at 80 1C. Brains were weighed and then homo-
genized in PBS at 20% w/v using a hand-held homogenizer and
disposable probes (Omni International). Samples were centri-
fuged at 1000xg for 10min, and supernatants were collected.
The level of infectious virus in supernatants was determined by
focus-forming assay on Vero cells or BSR-G cells as previously
described (Gomme et al., 2010; Wirblich and Schnell, 2010).
Histopathology and immunohistochemistry
Five-day-old Swiss Webster mice were inoculated i.c. with
1105 FFU of RVA or RVDG-GP. On days 1, 3, 5, 7, 9, 14, and 21,
three mice per group were sacriﬁced and brains were removed
from the cranium, immersion-ﬁxed in Bouin’s solution for 24 h,
post-ﬁxed in 70% isopropranol for 24–48 h, processed accordingto standard protocols, and embedded in parafﬁn. Two 4-mm
sections were obtained at the level of the hippocampus and at
the level of the cerebellum. One section from each area was
stained with hematoxylin and eosin (H&E) according to standard
protocols. Immunohistochemistry was performed on the second
section from each area. Sections ﬁrst underwent heat-induced
epitope retrieval (Biocare Rodent Decloaker, 10X, Biocare Medical,
Concord, CA) for 15 min at 95 1C, followed by incubation with a
biotinylated mouse anti-RABV nucleoprotein monoclonal anti-
body (1:50; MAB8724, Millipore, Temecula, CA) for 12 h at 4 1C.
Primary antibody was localized with horseradish peroxidase and
diaminobenzidine substrate followed by hematoxylin counter-
stain. Negative control slides were handled identically except that
non-immune serum was used in place of the primary antibody.
All slides were randomized, blinded, and examined by light
microscopy by a board-certiﬁed veterinary pathologist. Inﬂam-
mation and immunohistochemical staining were semi-quantita-
tively scored on a 0–3 scale (0¼none, 1¼mild, 2¼moderate,
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